Home » Stocks » CPHI

China Pharma Holdings, Inc. (CPHI)

Stock Price: $0.472 USD -0.014 (-2.92%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 20.58M
Revenue (ttm) 10.98M
Net Income (ttm) -20.40M
Shares Out 43.58M
EPS (ttm) -0.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $0.472
Previous Close $0.487
Change ($) -0.014
Change (%) -2.92%
Day's Open 0.487
Day's Range 0.460 - 0.487
Day's Volume 490,377
52-Week Range 0.222 - 1.400

More Stats

Market Cap 20.58M
Enterprise Value 25.24M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 43.58M
Float 21.94M
EPS (basic) -0.48
EPS (diluted) -0.47
FCF / Share -0.05
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 100,308
Short Ratio 0.18
Short % of Float 0.46%
Beta 0.45
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.87
PB Ratio 2.70
Revenue 10.98M
Operating Income -20.15M
Net Income -20.40M
Free Cash Flow -2.32M
Net Cash -4.66M
Net Cash / Share -0.11
Gross Margin 13.49%
Operating Margin -183.47%
Profit Margin -185.80%
FCF Margin -21.15%
ROA -6.43%
ROE -115.87%
ROIC -133.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$4.50*
Low
4.50
Current: $0.472
High
4.50
Target: 4.50
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue10.9212.3313.2115.5720.3522.1332.8154.5181.1774.39
Revenue Growth-11.41%-6.67%-15.15%-23.49%-8.05%-32.53%-39.81%-32.85%9.11%-
Gross Profit1.481.972.473.221.462.67-0.4814.0828.9930.28
Operating Income-20.41-10.45-18.68-8.16-14.30-38.76-18.615.7621.7224.20
Net Income-20.70-10.75-19.28-9.18-15.41-39.55-20.014.6219.2723.41
Shares Outstanding43.5843.5843.5843.5843.5843.5843.5843.5843.5343.39
Earnings Per Share-0.48-0.25-0.44-0.21-0.35-0.91-0.460.110.440.54
EPS Growth--------75%-18.52%-
Operating Cash Flow0.611.880.842.903.356.158.603.645.247.79
Capital Expenditures-0.14-0.05-0.14-0.19-0.69-5.13-18.79-1.77-0.35-10.52
Free Cash Flow0.471.830.702.702.661.02-10.201.874.88-2.73
Cash & Equivalents1.232.482.783.756.255.756.334.134.133.69
Total Debt4.557.829.9311.1716.9517.9217.394.763.933.78
Net Cash / Debt-3.32-5.34-7.15-7.42-10.70-12.17-11.06-0.630.20-0.09
Assets22.2445.3859.9578.5296.51121158163156132
Liabilities13.0015.1816.8819.6123.8728.3424.6714.7213.9113.81
Book Value9.2430.2043.0758.9172.6492.74133149142118
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name China Pharma Holdings, Inc.
Country China
Employees 228
CEO Zhi Lin Li

Stock Information

Ticker Symbol CPHI
Stock Exchange NYSE American
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NYSEAMERICAN: CPHI

Description

China Pharma Holdings develops, manufactures, and markets generic and branded pharmaceutical, and biochemical products primarily to hospitals and private retailers in the People's Republic of China. The company offers products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. Its products include Cerebroprotein Hydroloysate injection to treat memory decline and attention deficit; Gastrodin injection for tiredness, loss of concentration, poor sleep, and traumatic syndromes of the brain; Propylgallate and Ozagrel Sodium to treat cerebral thrombosis, coronary heart disease, and after surgery complications; Alginic Sodium Diester injection for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Bumetanide to treat edema diseases; and Candesartan for hypertension. It also provides Roxithromycin dispersible tablets for pharyngitis and tonsillitis; Cefaclor dispersible tablets for tympanitis, lower respiratory tract infection, urinary tract infections, and skin/skin tissue infection; Cefalexin capsules for acute tonsillitis; Anhydroandrographolide for ischemic heart, cerebrovascular, and high lipoprotein blood diseases; Clarithromycin granules and capsules; and Naproxen Sodium and PseudophedrineHydrochlorida sustained release tablets. In addition, the company offers Hepatocyte growth-promoting factor, Tiopronin, Compound Ammonium Glycyrrhetate S, and Omeparzole for the treatment of digestive diseases. Further, it provides Vitamin B6 injection; and Granisetron Hydrochloride injection to treat nausea and vomiting caused by radiotherapy and chemotherapy during the treatment of malignant tumors. The company offers its products through distributors, as well as through its network of 16 sales offices and approximately 1,000 sales representatives. China Pharma Holdings, Inc. is headquartered in Haikou, the People's Republic of China.